In this context, GLP-1R agonists have been shown to affect the central nervous system and exhibit neuroprotective properties in animal models of several neurodegenerative diseases, including Alzheimers and Parkinsons disease, stroke, diabetic retinopathy, and ocular hypertension (McClean et al., 2011
(PubMed) Tucker KL, Qiao N, Scott T, Rosenberg I, Spiro A, 3rd
Professional society guidelines now recommend GLP therapy for cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease or multiple cardiac risk factors
They bind to the same receptors in the pancreas and brain to lower blood sugar and suppress appetite
Therefore, from the 50g to the 1kg bags, the serving counts are equivalent to Bulk Supplements corresponding quantities